Verita Technology Applications

Early Cancer Detection

There are more than 200 different cancers, however, early detection tests only exist for a handful of them.  The primary detection modalities include clinical symptoms, followed by imaging and then surgical biopsy.  Blood tests that incorporate genetic and proteomic information have the potential to indicate the presence of disease at an early stage, ideally, before symptoms occur. Unfortunately, due to limited options widely available today, many diagnoses occur at advanced stages 3 and 4 when symptoms are more difficult to control. When cancer is detected

Our goal when developing diagnostic tests for Early Cancer Detection (ECD), is to detect the presence of cancer from a single blood draw. at the earliest stages before disease spreads throughout the body, there are treatment options that have the potential to save lives on a global scale. 

To demonstrate the value of the Verita™ platform our scientists have built an innovative early cancer detection program that leverages exosomes and proteomics. This has been expanded to include the ExoLuminta Study on pancreatic cancer. 

Publications and Presentations

Our researchers have demonstrated the effectiveness of ECD and our technology by getting results published in several peer-reviewed publications and presented at scientific conferences. These results have demonstrated that we can detect cancers at early stages for many indications, including pancreatic, ovarian, and lung cancers.

Please use the links below to access some of our recent papers and presentations to learn more.